F-1/A: MEDI Group Faces Financial Headwinds Amid IPO Launch

MEDI Group Limited is launching an initial public offering on Nasdaq Capital Market to raise capital for expansion, despite recent revenue declines and significant going concern doubts.

Summary

• MEDI Group Limited is offering 3,333,333 Class A Ordinary Shares at an estimated price between US$4.00 and US$5.00 per share, aiming to raise US$15,000,000.
• Existing shareholders are also offering 4,272,222 Class A Ordinary Shares for resale, from which the company will not receive any proceeds.
• The company operates medical cosmetology and traditional beauty services in Hong Kong under the 'Doctors Concept' brand, with over two decades of experience.
• Net revenue decreased by 15.7% to US$3.25 million for the six months ended December 31, 2024, from US$3.86 million in the prior year period.
• Net income increased by 9.6% to US$981,922 for the six months ended December 31, 2024, from US$895,606 in the prior year period.
• For the fiscal year ended June 30, 2024, net revenue decreased by 24% to US$6.11 million from US$8.02 million in 2023.
• Net income for the fiscal year ended June 30, 2024, decreased by 68% to US$0.61 million from US$1.90 million in 2023, primarily due to increased audit fees and staff costs related to the offering.
• The company reported negative operating cash flows of US$611,480 for the six months ended December 31, 2024, and US$1,031,834 for the year ended June 30, 2024.
• Working capital deficits were US$8,313,163 as of December 31, 2024, and US$9,029,519 as of June 30, 2024, raising substantial doubt about the company's ability to continue as a going concern.
• The company plans to use net proceeds for R&D capacity (5%), geographical expansion (25%), general working capital (65%), and advisory fees (5%).
• MEDI Group will be a controlled company post-IPO, with the Controlling Shareholder owning 57.86% of total issued shares and 96.49% of total voting power (assuming no over-allotment exercise).

Sentiment

Score: 3

Explanation: The sentiment is cautious to negative due to significant financial challenges, including revenue decline, negative operating cash flows, substantial working capital deficits, and a going concern warning from auditors. While there are strategic growth plans and an IPO to raise capital, the underlying financial health and market conditions in Hong Kong present considerable risks.

Positives

• Net income increased by 9.6% for the six months ended December 31, 2024, reaching US$981,922.
• The company has a high customer retention rate, with approximately 2,600 customers holding unexpired prepaid packages, nearly 100% of whom are repeat customers.
• MEDI Group has over two decades of experience in providing medical cosmetology and traditional beauty treatments in Hong Kong.
• The company has established a strong market reputation, evidenced by awards like the Enterprise Quality Service Award (2019) and recognition as a Top Ten Sales Achievement Aesthetic Centre in Hong Kong by Galderma (2023, 2024).
• The company offers a broad range of beauty treatments and maintains stringent quality control measures.
• The company has a dual-class share structure, which allows the controlling shareholder to maintain significant voting power and strategic control.

Negatives

• Net revenue decreased by 15.7% for the six months ended December 31, 2024, and by 24% for the year ended June 30, 2024.
• Net income for the fiscal year ended June 30, 2024, significantly decreased by 68% compared to the previous year.
• The company experienced negative cash flows from operating activities for both the six months ended December 31, 2024 (US$611,480) and the year ended June 30, 2024 (US$1,031,834).
• Significant working capital deficits of US$8,313,163 as of December 31, 2024, and US$9,029,519 as of June 30, 2024, indicate liquidity challenges.
• The independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern.
• The decline in revenue is attributed to weak economic conditions in Hong Kong, competition from Shenzhen due to RMB depreciation, and a shrinking target customer base due to emigration.
• The company plans to close its Yuen Long shop on September 30, 2025, due to customer loss to mainland China service providers.
• The company has identified a material weakness in its internal control over financial reporting due to limited accounting personnel and resources for U.S. GAAP and SEC reporting requirements.
• Reliance on a single medical practitioner (Dr. Pang Sai Yau) for medical aesthetic services poses a risk if his services are lost or if malpractice claims arise, with limited indemnification value.
• The company's growth plans are hindered by the ability to employ, train, and retain skilled personnel in a competitive labor market.

Risks

• Reputation in the industry is critical to success, and negative publicity or undesirable treatment outcomes could cause significant harm.
• Operating in a highly competitive industry with rapidly changing market trends, technological upgrades, and new treatments, where competitors may have more resources.
• Demand for services is susceptible to changes in Hong Kong's economic conditions, geopolitical tensions between the U.S. and China, and consumer discretionary spending.
• A lack of qualified employees, including beauty professionals and medical practitioners, could significantly hinder growth plans and adversely affect operations.
• Potential liability for malpractice of medical practitioners and negligence of staff members, with existing insurance policies not covering all liabilities.
• Increasingly stringent regulations on the medical aesthetic services industry in Hong Kong could impose new restrictions and compliance costs.
• Substantial doubt about the company's ability to continue as a going concern due to negative operating cash flows, significant working capital deficiency, and accumulated deficits.
• Inability to develop innovative services in a timely manner to meet changing customer preferences and compete with new technologies.
• Limited control over the quality of beauty equipment and treatment devices, potentially leading to customer complaints and operational disruptions.
• Serious side effects from medical aesthetics procedures, while statistically insignificant, may occur and lead to legal proceedings, liabilities, and reputational damage.
• Unfavorable public perception of the overall medical aesthetic services industry could reduce demand for services.
• The business has been materially and adversely affected by the COVID-19 pandemic, and future pandemics could have similar or worse impacts.
• Reliance on the management team and key personnel, particularly Mr. Ng Hon Kin (CEO) and Dr. Pang Sai Yau (medical partner), with loss of their services posing a disruption risk.
• Growth strategy, including geographical expansion and broadening service offerings, may not be successful and could require substantial capital expenditure.
• Failure to protect trade secrets and know-how or successfully pursue infringement actions on intellectual properties.
• Material weaknesses in the system of internal control over financial reporting due to limited accounting personnel and resources.
• Reliance on an internally designed database system (CARE) and risks associated with timely backup and effective cybersecurity.
• Political risks associated with conducting business in Hong Kong, including potential intervention or influence from the PRC government and changes in legal/regulatory systems.
• Potential for Class A Ordinary Shares to be prohibited from trading in the United States under the HFCAA if the PCAOB is unable to inspect or investigate auditors located in Hong Kong for two consecutive years.
• Uncertainty regarding the application of PRC laws and regulations (e.g., Data Security Law, Personal Information Protection Law, New Overseas Listing Rules) to Hong Kong operations, potentially requiring approvals or leading to sanctions.
• An active trading market for Class A Ordinary Shares may not be established or maintained, leading to price volatility and liquidity issues.
• As a controlled company, the concentrated ownership by the Controlling Shareholder may limit other shareholders' ability to influence corporate matters.
• The public offering price being substantially higher than net tangible book value per share will result in immediate and substantial dilution for new investors.
• As an exempted company incorporated in the Cayman Islands and a foreign private issuer, the company may adopt home country corporate governance practices that differ from Nasdaq rules, potentially affording less protection to shareholders.
• Difficulties in effecting service of legal process, enforcing foreign judgments, or bringing actions in Hong Kong against the company or its management based on foreign laws.
• Class A Ordinary Shares may be subject to rapid and substantial price volatility unrelated to performance, especially due to a small public float and concentrated ownership.
• If securities or industry analysts do not publish research or publish unfavorable or inaccurate research, the market price and trading volume could decline.
• No expectation of paying dividends in the foreseeable future, requiring investors to rely on price appreciation for returns.
• Potential for short selling to drive down the market price of Class A Ordinary Shares.
• Management's discretion in using net proceeds from the offering may not produce income or increase share price.
• Additional and more stringent criteria from Nasdaq and U.S. government for emerging market companies could add uncertainties to the offering, business, share price, and reputation.

Future Outlook

The company intends to expand its market penetration in Southeast Asia, build research and development capabilities for medical cosmetology devices, services, and products, and further expand in existing markets. It also plans to launch its own branded skincare and beauty products. Management expects current operating results to be temporary and profitability to grow with the next economic cycle, aiming to restore the number of service centers to pre-COVID-19 levels and broaden service offerings to high-growth segments like male customers.

Management Comments

• Management believes the decline in net income for the year ended June 30, 2024, was mostly the result of increased audit fees and staff costs for this offering.
• Management believes the recent downturn in operating results is temporary due to the migration wave of target customers after COVID-19 and competition from low-priced services in mainland China, not reflecting the company's competitiveness.
• Management is optimistic in generating sufficient operating cash flows to meet working capital requirements for the year ended June 30, 2025, building on cost control initiatives.
• Management believes that a public listing status will enhance the corporate profile for the public and potential clients and investors.
• Mr. Ng Hon Kin, CEO, stated that the company relies on his overall management, strategic planning, and daily operations.
• Management determines the amount of provision needed for reinstatement costs based on current market prices and quotes from renovation companies.

Industry Context

The global medical aesthetic services industry is projected to grow at an 11% CAGR from 2023 to 2028, driven by increased focus on personal appearance and demand for aesthetic procedures, particularly non-surgical ones. Hong Kong's beauty and personal care market is expected to grow at a 1.9% CAGR between 2024 and 2028. However, the Hong Kong market faces challenges from increasingly stringent regulations, liability risks, competition from alternative products and home-use devices, and a reduced consumer base due to economic downturns and emigration to mainland China. The company's strategy to focus on medical aesthetic services aligns with the industry's high-growth segments.

Comparison to Industry Standards

• The global medical aesthetic services industry is projected to expand at a CAGR of 11% from 2023 to 2028, indicating a strong growth trend that MEDI Group aims to capitalize on with its focus on medical aesthetic services.
• The Hong Kong beauty and personal care market is projected to grow at a CAGR of 1.9% between 2024 and 2028, which is significantly lower than the global medical aesthetic services growth, suggesting MEDI Group operates in a slower-growing local market for its broader services.
• The company's high customer retention rate and focus on personalized, high-quality services at competitive prices differentiate it from competitors, which include smaller independent operators and larger franchises.
• The company's reliance on a single medical practitioner, Dr. Pang Sai Yau, for medical aesthetic services, while leveraging his pioneer status, contrasts with larger industry players that typically have a broader team of medical professionals, potentially increasing key person risk.
• The company's plan to expand into Southeast Asia (Malaysia and Singapore) targets markets with similar demographic profiles and growing demand for high-end services, aligning with regional growth opportunities identified by MarketsandMarkets for Asia Pacific countries.

Management Changes

Corporate Governance

Legal Proceedings

• No pending or, to the company's knowledge, threatened or contemplated legal actions, suits, or proceedings that might result in a Material Adverse Change or materially affect the company's ability to perform its obligations under the underwriting agreement.
• The company is inevitably exposed to potential liability from complaints, claims, and litigation from customers due to inherent health risks in services.
• Dr. Pang Sai Yau, the medical partner, has agreed to indemnify the company against losses from customer complaints regarding procedures performed by him if found negligent, though this indemnification is of limited value.
• Medicine suppliers will indemnify the company against losses resulting from their products.

Related Party Transactions

• Mr. Ng Hon Kin, Chairman, CEO, and ultimate shareholder, controls Global Medical Equipment Co., Ltd., Smart Key International Consultant Co., Ltd., and Be Health Co., Ltd., with which the company engages in transactions.
• Ms. Huang Weisi, a prior director of subsidiaries, also controlled Euro Cos Co., Ltd.
• Bank borrowings totaling HKD11,000,000 (US$1,410,256) were personally guaranteed by Ms. Huang Weisi, with Mr. Ng Hon Kin assuming these guarantees on April 2, 2024.
• Working capital transactions with Mr. Ng Hon Kin resulted in US$1,175,464 due to related parties as of December 31, 2024, which Mr. Ng agreed to collect after the public offering.
• Accounts payable to Global Medical Equipment Co., Ltd. and Euro Cos Co., Ltd. totaled US$4,448 as of December 31, 2024, for consumables.
• The company paid rental fees of US$30,366 to Be Health Company Limited for a sub-leased property for the six months ended December 31, 2024.
• Management fees of US$14,817 were paid to Smart Key International Consultant Company Limited for administrative office lease for the six months ended December 31, 2024.
• Salaries and employee benefits paid to Mr. Ng Hon Kin by an associated company amounted to US$8,091 for the six months ended December 31, 2024, and US$15,385 for the year ended June 30, 2024.
• Promissory notes totaling US$1,038,000 from seven individuals were cancelled on March 28, 2024, in exchange for Ordinary Shares issued to entities designated by the noteholders.

Stakeholder Impact

• Shareholders: New investors will experience immediate and substantial dilution (US$4.35 per share) due to the offering price being significantly higher than the net tangible book value. The dual-class share structure concentrates voting power with the controlling shareholder, limiting influence for other shareholders. The going concern risk poses a threat of complete loss of investment.
• Employees: The company plans to expand its beauty professional team from 1 medical practitioner and 19 therapists to 3 medical practitioners and 40 therapists, indicating potential job growth. However, the closure of the Yuen Long shop will result in 7 employees being affected, though the company will only have 35 employees until a new shop opens.
• Customers: The company aims to enhance customer loyalty through high-quality, personalized services and expand offerings. However, customer loss in Yuen Long to mainland China providers indicates competitive pressures and changing consumer behavior. Potential service disruptions from employee shortages or quality issues could negatively impact customer satisfaction.
• Suppliers: The company maintains relationships with third-party distributors for injectables and equipment, and its financial stability could impact its ability to settle payments.
• Creditors: The company's significant working capital deficit and negative operating cash flows raise concerns about its ability to meet financial obligations, although it intends to rely on IPO proceeds, bank borrowings, and shareholder loans.

Next Steps

• Complete the initial public offering and listing on the Nasdaq Capital Market.
• Set up research and development capacity, allocating approximately 5% of net IPO proceeds.
• Penetrate and further expand into new and existing geographical markets, allocating approximately 25% of net IPO proceeds, with interest in Malaysia and Singapore.
• Utilize approximately 65% of net IPO proceeds for general working capital and other general corporate purposes.
• Pay approximately 5% of net IPO proceeds as advisory fees.
• Close the Yuen Long shop on September 30, 2025, and open a new shop in another location in Hong Kong.
• Expand service offerings to cater to high-growth segments, including male customers and new skincare regimens.
• Upgrade and broaden service offerings by monitoring advanced medical grade equipment and developing new treatments.
• Invest in software technology for real-time operational monitoring, centralized information exchange, and data analytics.
• Recruit, train, and maintain a team of experienced management and senior beauty professionals, aiming to expand the beauty professional team from 1 medical practitioner and 19 therapists to 3 medical practitioners and 40 therapists.
• Monitor and comply with evolving PRC and Hong Kong regulatory requirements, particularly regarding data security and overseas listings.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by substantial working capital deficits, negative operating cash flows, and an explicit 'going concern' warning from its auditors. While the IPO aims to raise capital, the underlying business performance shows significant revenue decline and a sharp drop in net income for the last fiscal year. The dual-class share structure also limits minority shareholder influence. The high dilution for new investors, coupled with significant operational and regulatory risks (especially related to Hong Kong/PRC), makes this a highly speculative investment with a high probability of capital loss. A seasoned investor would likely avoid this offering due to the fundamental financial instability and high risk profile.

Keywords

Medical Cosmetology, Beauty Services, Hong Kong, IPO, Nasdaq, SEC Filing, F-1/A, Financial Performance, Risk Factors, Corporate Governance, Going Concern, Dual-Class Shares, PRC Regulation, HFCAA, PCAOB, Capital Raise, Expansion Strategy, Customer Retention, Doctors Concept